Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Dec 08, 2011	EDAP Confirms Robotic Ablatherm(R)-HIFU Position as 'Must Have' Complement to Prostate Cancer Surgery at Two Major Scientific Conferences Ablatherm-HIFU Featured in Eight Presentations at World Congress of Endourology (WCE) Ablatherm-HIFU Focal Treatment Advantages Showcased at First Montreal Conference on Focal Therapy LYON, France , Dec. 8, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic	View HTML EDAP Confirms Robotic Ablatherm(R)-HIFU Position as 'Must Have' Complement to Prostate Cancer Surgery at Two Major Scientific Conferences 16.1 KB
Toggle Summary Apr 09, 2007	EDAP Concludes HealthTronics Agreement Company Reclaims Full US Market Rights; Ablatherm-HIFU Trial to Resume Immediately	View HTML EDAP Concludes HealthTronics Agreement 13.3 KB
Toggle Summary Aug 17, 2012	EDAP Completes Follow-Up Phase and Data Collection for FDA ENLIGHT Trial LYON, France , Aug. 17, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided an update regarding its Ablatherm-HIFU ( High Intensity Focused Ultrasound ) ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer.	View HTML EDAP Completes Follow-Up Phase and Data Collection for FDA ENLIGHT Trial 15 KB
Toggle Summary Mar 20, 2014	EDAP Completes FDA Q&A Session for Its Ablatherm-HIFU Pre-Market Approval Application LYON, France , March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step	View HTML EDAP Completes FDA Q&A Session for Its Ablatherm-HIFU Pre-Market Approval Application 15.6 KB
Toggle Summary Jun 27, 2014	EDAP Completes FDA Inspection of Manufacturing Site FDA Inspector Reported no Findings From the Scheduled Facility Audit	View HTML EDAP Completes FDA Inspection of Manufacturing Site 14.9 KB
Toggle Summary Aug 05, 2014	EDAP Comments on FDA Panel Vote Responds to Gastroenterology and Urology Devices Panel Vote on Ablatherm-HIFU for Treatment of Prostate Cancer LYON, France , Aug. 5, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today provided comments on the recent Gastroenterology and Urology	View HTML EDAP Comments on FDA Panel Vote 17.2 KB
Toggle Summary Jun 03, 2014	EDAP Closes $9.3 Million Registered Direct Offering Positions Company to Advance on Preparing U.S. Operations in Connection with FDA Advisory Committee Meeting and PMA process	View HTML EDAP Closes $9.3 Million Registered Direct Offering 13.9 KB
Toggle Summary Mar 06, 2017	EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. LYON, France , March 6, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the appointment of Noah J. Bartsch as Vice President of Global Medical, Regulatory, and	View HTML EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. 23.1 KB
Toggle Summary Jan 06, 2010	EDAP Appoints U.S. Vice President of Sales and Marketing Enhances Strategy to Drive U.S. Sonolith I-Sys Device Sales	View HTML EDAP Appoints U.S. Vice President of Sales and Marketing 14.7 KB
Toggle Summary Jun 26, 2009	EDAP Appoints U.S. Urologist Dr. Argil Wheelock to Board of Directors LYON, France, Jun 26, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Dr. Argil J. Wheelock, MD was appointed to its Board of Directors, effective June 25, 2009. Dr. Wheelock replaces Dr.	View HTML EDAP Appoints U.S. Urologist Dr. Argil Wheelock to Board of Directors 15.2 KB